Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/14/2021 01/15/2021 01/18/2021 01/19/2021 01/20/2021 Date
312.05(c) 316.65(c) 314.95(c) 318.2(c) 318.35 Last
1 848 324 2 350 861 1 434 363 1 225 765 248 222 Volume
+0.02% +1.47% -0.54% +1.03% +0.05% Change
More quotes
Financials
Sales 2020 59 737 M 67 188 M 67 188 M
Net income 2020 14 387 M 16 181 M 16 181 M
Net cash position 2020 3 176 M 3 572 M 3 572 M
P/E ratio 2020 19,5x
Yield 2020 2,92%
Sales 2021 61 728 M 69 427 M 69 427 M
Net income 2021 15 176 M 17 069 M 17 069 M
Net cash position 2021 10 902 M 12 262 M 12 262 M
P/E ratio 2021 18,3x
Yield 2021 3,02%
Capitalization 273 B 307 B 307 B
EV / Sales 2020 4,52x
EV / Sales 2021 4,25x
Nbr of Employees 97 735
Free-Float 83,6%
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The... 
Sector
Pharmaceuticals
Calendar
01/28Presentation
More about the company
Notations Surperformance© of Roche Holding AG
Trading Rating : Investor Rating :
More Ratings
All news about ROCHE HOLDING AG
02:26aROCHE HOLDINGS AG : Jefferies maintains a Buy rating
MD
01/19CHUGAI PHARMACEUTICAL : Supports the Japan Climate Initiative's Calling to Raise..
AQ
01/18ROCHE ANNUAL GENERAL MEETING 2021 : Exercising of shareholder rights via the ind..
AQ
01/18PRESS RELEASE : Roche Annual General Meeting 2021: Exercising of shareholder rig..
DJ
01/15ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating
MD
01/14Qiagen warns against using standard tests to track coronavirus variants
RE
01/13CHUGAI PHARMACEUTICAL : Conducts Digital Transformation in Manufacturing with IB..
AQ
01/13ROCHE : Exane BNP Paribas Lowers Price Target on Roche, Maintains Outperform Rec..
MT
01/13ROCHE HOLDINGS AG : JP Morgan reiterates its Neutral rating
MD
01/12ROCHE : Unit Regeneron to Supply Additional Doses of COVID-19 Antibody Cocktail ..
MT
01/12ROCHE : confirms US government agreement to purchase additional doses of Regener..
AQ
01/12PRESS RELEASE : Roche confirms US government -2-
DJ
01/12PRESS RELEASE : Roche confirms US government agreement to purchase additional do..
DJ
01/12ROCHE : CHEPLAPHARM acquires the rights to Rivotril
AQ
01/12ROCHE HOLDINGS AG : Receives a Buy rating from UBS
MD
More news
News in other languages on ROCHE HOLDING AG
02:26aROCHE HOLDINGS AG : Jefferies favorable sur le dossier
01/19Aktien Schweiz verteidigen Anfangsgewinne nicht
01/18ROCHE : prochaine AG sans présence physique des actionnaires
01/18Roche-Generalversammlung findet ohne physische Anwesenheit der Aktionäre stat..
01/18GLOBENEWSWIRE/ORDENTLICHE ROCHE GENE : Abstimmungen und Wahlen durch die unabhän..
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Stock Trading Strategies
ROCHE HOLDING AG - 2020
Close to an important medium term support level
BUY
More Stock Trading Analysis
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 363,84 CHF
Last Close Price 318,20 CHF
Spread / Highest target 37,0%
Spread / Average Target 14,3%
Spread / Lowest Target -10,4%
EPS Revisions
Managers and Directors
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG2.98%307 190
JOHNSON & JOHNSON3.43%428 525
NOVARTIS AG2.24%218 823
MERCK & CO., INC.1.70%210 474
PFIZER INC.-0.22%204 160
ABBVIE INC.4.69%198 051